Introduction
Kaposi's Sarcoma (KS) is the leading cancer in parts of subSaharan Africa and in AIDS patients world-wide (Antman and Chang, 2000) . KS is histopathologically characterized by having a high degree of angiogenesis, infiltrating immune and red blood cells, and is predominantly comprised of spindle cells, which are of endothelial origins and specifically express markers of lymphatic endothelium (Boshoff et al., 1995; Jussila et al., 1998; Skobe et al., 1999) . In addition, KS tumors have elevated levels of many cytokines and growth factors, including interleukin-1 (IL-1), IL-6, basic fibroblast growth factor (bFGF), platelet derived growth factor (PDGF), tumor necrosis factor (TNF), interferon gamma (IFN-g), and vascular endothelial growth factor (VEGF) (Ensoli et al., 2001 (Ensoli et al., , 2000 Wang et al., 2004 ).
Kaposi's Sarcoma-associated herpesvirus (KSHV or human herpesvirus-8) is the etiologic agent of KS, and is classified as a gamma-2-herpesvirus (Aluigi et al., 1996; Chang et al., 1994) . The KS spindle cell is infected by KSHV, with greater than 95% of cells latently infected and 1-5% of cells undergoing lytic replication (Staskus et al., 1997) . KSHV encodes over 90 genes, but only a few genes are expressed during latency in KS tumors and KSHV-infected endothelial cells in culture: latency associated nuclear antigen (LANA), viral Cyclin, viral FLICE inhibitory protein (vFLIP) (Dittmer et al., 1998; Staskus et al., 1997) , the kaposin family (Sadler et al., 1999) , and 17 or more microRNAs (Cai et al., 2005; Grundhoff et al., 2006; Pfeffer et al., 2005; Samols et al., 2005) . Additionally, several KSHV lytic genes have been proposed to contribute to KS pathogenesis in an autocrine or paracrine fashion from the small percentage of lytically infected cells found in KS tumors. Some of these genes include: a constitutively active viral G-protein coupled receptor (vGPCR); K1, which signals through a constitutive ITAM (immunoreceptor tyrosine-based activation motif), K15, a membrane protein with SH2 and SH3 protein binding domains and vIL-6, a viral homolog of human IL-6 (Brinkmann et al., 2003; Couty and Gershengorn, 2004; Lagunoff et al., 1999; Molden et al., 1997) . Interestingly, transcripts for K1 and vIL-6 were recently shown to be detectable in dilutions of primary effusion lymphoma cells where other lytic genes could no longer be detected, indicating there may be some previously unappreciated low-level of expression of these genes during latency (Chandriani and Ganem, 2010) . Additionally, there are specific situations where vIL-6 expression can be induced during latency. For example, it was shown that interferon could activate expression of vIL-6 in primary effusion lymphoma (PEL) cells (Chatterjee et al., 2002) .
KSHV infection of blood endothelial cells (BECs) induces their differentiation to lymphatic endothelial cells (LECs) (Carroll et al., 2004; Hong et al., 2004; Wang et al., 2004 blood and lymphatic vasculatures respectively, and differentially express around 300 genes . During embryonic development, the blood vessel system develops first, then BECs differentiate into LECs in the cardinal vein when an unknown signal induces the expression of the homeobox transcription factor Prox1 Hong et al., 2002; Petrova et al., 2002) . Prox1 is a transcriptional repressor and activator, and is the master regulator of lymphatic differentiation Hong et al., 2002; Petrova et al., 2002) . Following Prox1 induction, vascular endothelial growth factor receptor 3 (VEGFR-3) is expressed on LECs and is responsible for budding and formation of early lymph vessels through binding its ligand VEGF-C (Veikkola et al., 2001) . Podoplanin, a cell surface glycoprotein induced by Prox1 expression, is involved in later stages of lymphatic vasculature development . KSHV infection of primary BECs or telomerase-immortalized microvascular endothelial (TIME) cells, which resemble BECs in gene expression profile, induces the expression of Prox1, VEGFR-3 and podoplanin (Carroll et al., 2004; Hong et al., 2004; Wang et al., 2004) .
The viral mechanism of KSHV-induced endothelial cell differentiation is poorly understood. Previously, we found that KSHV induction of lymphatic differentiation is dependent on the activation of the cytokine receptor gp130, and the resulting initiation of JAK2/STAT3 and PI3K/AKT intracellular signaling pathways (Morris et al., 2008; Punjabi et al., 2007) . In addition, the latently expressed kaposin B was recently shown to stabilize Prox1 mRNA, leading to an increase in expression of Prox1 and its downstream-activated genes, such as VEGFR-3 (Yoo et al., 2010) . However, kaposin B expression was unable to induce the expression of Prox1 in cells that do not already express Prox1, namely blood endothelial cells. This suggests that there must be a viral gene that initially induces the expression of Prox1 and lymphatic endothelial cell differentiation, and kaposin B subsequently increases or maintains expression of genes involved in the differentiation phenotype.
KSHV-encoded vIL-6 shares $25% homology with human IL-6, but can bind the gp130 receptor directly and signal independent of the cognate IL-6 receptor (gp80) to initiate similar intracellular signaling pathways (Li et al., 2001; Molden et al., 1997; Moore et al., 1996; Nicholas et al., 1997; Wan et al., 1999) . In PEL cells, which are KSHV-infected, vIL-6 promotes proliferation of cells, protects cells from apoptosis, and also promotes immune evasion of interferon activity (Chatterjee et al., 2002; Foussat et al., 1999; Jones et al., 1999) . vIL-6 can also promote angiogenesis through induction of VEGF A . In this report, we show that the genes from the major latency locus do not have the capacity to induce lymphatic endothelial cell markers when expressed individually. Interestingly, expression of KSHV vIL-6 is sufficient to induce the LEC-specific markers Prox1, VEGFR-3, and podoplanin. We also extend previous findings that vIL-6 is not necessary in the context of KSHV infection, and demonstrate that vIL-6 is not the soluble factor released by KSHV-infected cells that activates gp130 receptor signaling (Morris et al., 2008; Punjabi et al., 2007) . Thus, while vIL-6 is sufficient for endothelial cell differentiation, another unidentified viral protein directly activates or induces a novel cytokine that activates the same pathway during latency. The presence of multiple viral factors that induce the same pathway suggests that this cytokine-signaling pathway plays a central role in KSHV pathogenesis and KS tumor formation.
Results

KSHV latent genes do not activate gp130 receptor signaling or lymphatic differentiation of endothelial cells
In previous reports, we determined that viral gene expression is necessary to maintain KSHV-induced STAT3 activation and lymphatic reprogramming (Morris et al., 2008; Punjabi et al., 2007) . These results suggest that viral genes are required for the constant activation of the gp130 receptor signaling pathway. Since latently infected TIME cells express LEC-specific markers and display persistent STAT3 activation (Carroll et al., 2004; Punjabi et al., 2007) , we hypothesized that one or more of the latent genes are responsible for KSHVinduced activation of gp130 receptor signaling and thus lymphatic differentiation of endothelial cells. The latent genes viral Cyclin (vCyc), kaposin A (KapA), kaposin B (KapB), and kaposin C (KapC) were cloned into a mammalian expression vector with an N-terminal 3XFLAG epitope-tag and expressed in TIME cells. Additionally, we obtained a mammalian expression vector encoding a highly expressed codon-optimized FLAG-tagged vFLIP, which was also expressed in TIME cells (P. Bellare and D. Ganem, unpublished data) . Previous studies have verified the functionality of N-terminally tagged vCyc, vFLIP, and KapA (Montaner et al., 2003) . We verified the expression of all constructs by transient transfection into TIME cells followed by immunoblot analysis with an anti-FLAG antibody (Fig. 1A, bottom panel) . Anti-vCyc and anti-kaposin antibodies were used to verify the expression of the FLAG-tagged vCyc, KapB, and KapC constructs (data not shown). The transfection efficiency was 50-70%, as determined by transfection of TIME cells with a plasmid encoding green fluorescent protein (GFP) and monitoring expression by fluorescence microscopy (data not shown). At 48 h post infection, cells were harvested for Western blot analysis. None of the latent viral proteins tested activated STAT3, as determined by STAT3 Fig. 1 . Transient expression of latent genes do not induce lymphatic differentiation. (A) Constructs expressing individual latent viral genes were transiently transfected into TIME cells. 48 h post transfection, cell lysates were harvested and subjected to immunoblot analysis with the indicated antibodies. In addition, stable pooled TIME cells expressing LANA or a retroviral vector control were similarly analyzed. While expression of individual latent viral genes was confirmed by FLAG or LANA immunoblot, no viral gene activated STAT3 or induced VEGFR-3 expression. (B) TIME cells (2 Â 10 5 ) were transduced with lentiviral preps of the indicated KSHV latent genes or pCGSW, a control lentivirus that expresses GFP. 72 hpi, cell lysates were harvested and subjected to immunoblot analysis with the indicated antibodies. TIME cells were mock or KSHV-infected and harvested 48 hpi for positive and negative controls respectively. phosphorylation at Tyr705 (pSTAT3), VEGFR-3 or podoplanin expression ( Fig. 1A and not shown). We also created a stable pooled TIME cell line expressing LANA or an empty vector control cell line (pZIP) using retroviral transduction, followed by puromycin selection. Although the expression of LANA in these cells was confirmed by immunoblot analysis with an anti-LANA antibody (Fig. 1A , lower right panel), LANA expression was not sufficient to induce persistent STAT3 phosphorylation or VEGFR-3 expression in TIME cells when compared to the vector control cell line. These results indicate that transient expression of the individual latent genes, LANA, vCyc, KapA, KapB, KapC, or vFLIP, is not sufficient to induce gp130 receptor activation or lymphatic differentiation. Furthermore, we did not see STAT3 phosphorylation when all of the latent gene constructs were co-transfected into TIME cells, although expression levels were lower than when they were transfected individually (data not shown).
To examine longer-term expression of the latent genes in a higher percentage of cells, we obtained lentiviral vectors of the latent genes, including K12 (KapA), ORF71 (vFLIP), ORF72 (vCyc), and ORF73 (LANA). Infectious lentivirus containing each major latent gene was used to infect TIME cells. TIME cells were transduced with the KSHV lentiviral library and expression of the viral genes was confirmed for each by qRT-PCR with latent gene specific primers (see Supplemental Fig. 1 ). TIME cells were infected with the different lentiviral preparations in parallel, and protein lysates were harvested at 72 hpi. Mock-and KSHVinfected TIME cell lysates harvested 48 hpi were used as negative and positive controls respectively. As with the transient transfections, none of the genes from the latent locus were able to induce STAT3 activation, AKT activation as determined by phoshphorylation at Ser473 or lymphatic endothelial cell markers (Fig. 1B) . KapB was previously reported to stabilize the mRNA of Prox-1 and subsequently increase VEGFR3 expression in LECs, though it did not induce the expression of Prox-1 in BECs (Yoo et al., 2010) . To confirm this in TIME cells, we used a lentivirus vector to express a FLAG-tagged KapB protein. As expected, KapB expression did not induce any Prox-1 transcription in TIME cells as determined by quantitative RT-PCR (data not shown).
KSHV vIL-6 induces LEC-specific markers in TIME cells
Since expression of KSHV latent genes did not activate STAT3 or induce LEC-specific markers, we postulated that the small percentage of lytically infected TIME cells could be producing a paracrine factor to activate the gp130 receptor. Additionally, a recent publication found that vIL-6 mRNA could be detected by PCR in dilutions of PEL cells where many other lytic mRNAs could not be detected (Chandriani and Ganem, 2010 ). Therefore, we tested vIL-6 and a select number of KSHV lytic genes for activation of the gp130 receptor by transient transfection. These include K14 (vOX2), hemagglutinin (HA)-tagged K3 (MIR1), FLAG-tagged K5 (MIR2), or the vector controls pBMN-ZIN and pLNCX2. Of the genes tested, only vIL-6 was able to activate STAT3 and turn on expression of VEGFR3 ( Fig. 2A) . To determine if KSHV ORF50 (Rta), the lytic switch gene, activates STAT3 and lymphatic differentiation, we infected TIME cells with an adenovirus vector expressing Rta. While the levels of Rta used were sufficient to induce lytic reactivation in latently infected cells, in uninfected cells Rta expression did not lead to activation of STAT3 and did not increase Prox-1 expression (data not shown).
We next used a lentiviral expression library of select KSHV genes: K1, K2 (vIL-6), K3 (MIR1), ORF28, K6 (vMIP), K8 (K-bZIP), K9 (vIRF1), K11.1 (vIRF2), ORF74 (vGPCR), and K15-P (LAMP) to test which KSHV lytic genes could induce lymphatic endothelial cell differentiation. This lentiviral library was previously used to identify the viral genes that induce Ang2 expression in endothelial cells (Vart et al., 2007) . Again, K2 (vIL-6) was the only viral gene tested that induced persistent STAT3 phosphorylation (Fig. 2B and data not shown). Conditioned media from cells transduced with each KSHV gene examined was also tested for activation of STAT3 and again, only conditioned media from vIL-6 expressing cells led to phosphorylation of STAT3 (Supplemental Fig. 2) . Interestingly, vGPCR and K1 induced low levels of AKT activation in this assay while in cells with long-term vIL-6 expression the levels of phosphorylated AKT were at our limits of detection. However, as described below and seen in Fig. 5B , treatment of cells with conditioned media containing vIL-6 induces stronger activation of AKT indicating that vIL-6 can transiently induce AKT. Overall, this data indicates that activation of AKT is important for blood to lymphatic endothelial cell differentiation, but activation of AKT alone is not sufficient to induce blood to lymphatic endothelial cell differentiation as both K1 and vGPCR induce the activation of AKT but do not activate STAT3 or significantly increase the expression of VEGFR3.
We then selected for cells that had been transduced with a retrovirus expressing vIL-6 or a vector control to make a stable vIL-6 cell line and a passage matched control vector cell line (pBMN-ZIN). The stable vIL-6 TIME cell line induced long-term activation of STAT3 and long-term VEGFR-3 and podoplanin protein expression similar to levels seen in KSHV infected cells as determined by Western blot analysis (Fig. 3A ). There were also highly induced levels of Prox1 mRNA in vIL-6 stable cells but not in the vector control cells (Fig. 3B) . Prox1 is the transcription factor necessary for the induction of lymphatic differentiation in vivo and in vitro. Previously, we determined that gp130 receptor expression is induced by KSHV infection of TIME cells, and this induction was controlled by STAT3 activation (Morris et al., 2008; Punjabi et al., 2007) . Accordingly, we also observed an increase in gp130 mRNA induction in the vIL-6-expressing TIME cells (Fig. 3B ). These results demonstrate that vIL-6 expression is sufficient to activate gp130 receptor signaling and induce lymphatic differentiation of TIME cells.
KSHV vIL-6 induces LEC-specific markers in primary blood endothelial cells
The previous analysis was performed in an immortalized blood endothelial cell line, TIME cells. We also confirmed that vIL-6 was sufficient to reprogram primary human dermal blood microvascular endothelial cells (BECs) to express lymphatic endothelial cell markers. Primary BECs (Lonza) were transduced with a lentivirus expressing vIL-6 or the control vector lentivirus pCGSW and lysates were harvested 72 h after transduction. Immunoblot analysis shows that vIL-6 induces the activation of STAT3 and the expression of VEGFR3 in primary BECs (Fig. 4) .
vIL-6 induction of lymphatic differentiation requires JAK2/STAT3 and PI3K/AKT signaling We observed persistent phosphorylation of STAT3 in stable vIL-6 expressing TIME cells, but very weak phosphorylation of AKT (Fig. 2B) . We therefore wanted to determine if JAK2/STAT3 and PI3K/AKT signaling were necessary for vIL-6 activation of lymphatic endothelial cell markers. TIME cells expressing vIL-6 were treated with pharmacological inhibitors of PI3K (LY294002), and of JAK2 (AG490). Both inhibitors blocked vIL-6 induced expression of VEGFR3 and podoplanin (Fig. 5A) . Therefore, as with KSHV latent infection, both JAK2/STAT3 and PI3K/AKT signaling is necessary for induction of lymphatic endothelial cell reprogramming by vIL-6.
Since the levels of AKT activation in the vIL-6 cell line was at the limit of detection, we tested whether vIL-6 could transiently activate AKT in TIME cells. Conditioned media from vIL-6-expressing or control pBMN-ZIN TIME cells were harvested, and used to treat serum-starved TIME cells for 30 min. Both AKT and STAT3 were transiently phosphorylated in cells treated with conditioned media from vIL-6-expressing TIME cells (Fig. 5B) . This result indicates that while vIL-6 expression persistently activates STAT3 in TIME cells, AKT activation is mostly transient. However, there appears to be some low-level activation of AKT in long term vIL-6 expressing endothelial cells as the PI3 kinase inhibitor, LY294002 inhibited vIL-6 activation of VEGFR3. However, because long-term activation is at our limit of detection, it was not seen consistently in every experiment. Nonetheless, this indicates that vIL-6 can, at least transiently, activate AKT signaling and this activation is necessary for the induction of lymphatic markers by vIL-6. vIL-6 is not essential for activation of gp130 receptor signaling in KSHV-infected endothelial cells While vIL-6 expression alone is sufficient to induce STAT3 activation in TIME cells, we previously showed that vIL-6 is not necessary for activation of STAT3 nor the induction of LEC-specific markers in the context of KSHV infection (Punjabi et al., 2007) . For those experiments, we used a recombinant virus where more than half of the ORFK2 gene encoding vIL-6 is deleted, and infected TIME cells with either vIL-6-positive or negative-recombinant KSHV isolates. In both cases, we observed phosphorylation of STAT3 and induction of VEFGR-3 and podoplanin Morris et al., 2008; Punjabi et al., 2007) . However, it is still possible that vIL-6 plays a significant role in the activation of STAT3 and VEGFR3 that is masked by comparing the infections of the recombinant virus versus the control virus. Additionally, the deletion of vIL-6 leaves a small portion of the gene intact, though ) were transiently transduced with lentiviral preps of the indicated KSHV lytic genes or a control lentivirus (pCGSW). 72 hpi, cell lysates were harvested and subjected to immunoblot analysis with the indicated antibodies. TIME cells were mock or KSHVinfected and harvested 48 hpi for positive and negative controls respectively. Fig. 3 . Stable vIL-6 expression in TIME cells induces LEC-specific markers. (A) Stable vIL-6-expressing TIME cells induce VEGFR-3 and podoplanin expression compared to stable TIME cells expressing retroviral vector alone (pBMN-ZIN) as determined by immunoblot analysis. Mock and KSHV-infected TIME cells harvested 48 hpi were used as negative and positive controls. Stable vIL-6-expressing TIME cells also display persistent activation of STAT3 (B) Stable vIL-6-expressing TIME cells induce Prox1 and gp130 mRNA expression as determined by quantitative real-time RT-PCR. Error bars represent standard error of the mean (n¼ 3). were transiently transduced with lentiviral preps of vIL-6 lytic or control lentivirus (pCGSW). 72 hpi, cell lysates were harvested and subjected to immunoblot analysis with the indicated antibodies. Primary BECs were mock or KSHVinfected and harvested 48 hpi for positive and negative controls respectively.
we could not detect expression of the vIL-6 transcript in this recombinant . To determine if vIL-6 is the dominant gp130-activating factor and that the infection with the recombinant is not equivalent to infection with the control, we used lentivirus-mediated delivery of shRNA specific to vIL-6. TIME cells were infected with KSHV, and subsequently infected with lentivirus expressing vIL-6 shRNA or a negative control nonspecific shRNA (NS) (Chen et al., 2009 ). By quantitative real-time RT-PCR, we observed a 60% decrease in vIL-6 mRNA in the vIL-6 versus the NS shRNA transduced KSHV-infected cells, normalizing to cellular GAPDH mRNA levels (data not shown and (Chen et al., 2009) ). Importantly, there was no decrease in mRNA levels of the latent gene LANA, indicating the establishment of KSHV infection was not impaired (data not shown). However, vIL-6 shRNA did not significantly decrease KSHV induction of VEGFR-3 or STAT3 activation (Fig. 6A) In the next set of experiments we examined the ability of the shRNA to block activation of STAT3 by conditioned media from KSHV infected TIME cells and from vIL-6 expressing TIME cells to determine if vIL-6 is the dominant factor in transient activation of STAT3 in KSHV infected cells. TIME cells were co-transduced with a K2 (vIL-6) expressing lentivirus and either vIL-6 specific or NS shRNA lentiviruses and the conditioned media was harvested 48 h later. The vIL-6 specific shRNA strongly inhibited the activation of STAT3 by conditioned media from vIL-6 expressing cells (Fig. 6) . However, there was little or no decrease in the activation of STAT3 by conditioned media from KSHV-infected cells in the presence of vIL-6 specific shRNA, indicating that vIL-6 is not necessary for a significant portion of the activation of gp130 by conditioned media during de novo KSHV infection. This set of experiments shows that the vIL-6-independent activation of STAT3 and lymphatic differentiation is likely the predominant pathway in latent KSHV-infected cells.
Discussion
KSHV infection of endothelial cells, the main cell type of KS tumors, induces the aberrant activation of the cytokine receptor gp130, resulting in the persistent activation of the JAK2/STAT3 and PI3K/AKT signaling pathways. These pathways result in KSHVmediated transcriptional reprogramming of endothelial cells to a LEC differentiation state (Morris et al., 2008) . In this study we sought to determine whether specific viral proteins could activate gp130 receptor signaling or LEC-specific genes. Using transient transfection or lentiviral transduction of individual viral genes, we could not identify a latent protein that activated STAT3 or induced LEC-specific markers. We went on to test a number of lytic genes that have been previously shown to play a role in KSHV pathogenesis during latency through cytokine signaling or other paracrine effects. Interestingly, although the KSHV lytic proteins vGPCR and K1 can activate PI3K/AKT signaling in other systems (Sodhi et al., 2004; Wang et al., 2006) , individual expression of these viral genes did not induce lymphatic reprogramming in TIME cells indicating that activation of PI3K/AKT signaling alone is not sufficient for BEC to LEC differentiation. A number of other lytic genes that can act as cytokines like the vMIPs were also unable to activate STAT3 signaling or induce LEC-specific markers. However, we found that KSHV-encoded vIL-6, which can bind and activate the gp130 receptor, induces LEC-specific markers through activation of both JAK2/STAT3 and PI3K/AKT signaling pathways. Interestingly, both STAT3 and AKT are phosphorylated early after KSHV infection of endothelial cells, dephosphorylated at 4-8 hpi and then constitutively activated after 12 h (Punjabi et al., 2007; Sadagopan et al., 2007) . The early activation of STAT3 is due to viral binding and entry while the late activation of STAT3 is due to viral gene expression as UV-irradiated virus only activates the early wave of STAT phosphorylation (Punjabi et al., 2007) . We previously published that in latently infected cells gp130 signaling was necessary for KSHV induced differentiation of blood endothelial cells to lymphatic. Here we found that activation of these pathways by vIL-6 expression alone was sufficient to induce lymphatic reprogramming of both TIME and primary microvascular blood endothelial cells. Additionally, while it was known that vIL-6 could activate STAT3 through the gp130 receptor, we found here that at least transiently, vIL-6 could activate AKT. While vIL-6 has been shown to predominantly signal through intracellular pathways, we found that conditioned media from cells expressing vIL-6 could also activate STAT3 and AKT indicating it can act both cell autonomously and as a paracrine factor.
Our previous studies found that blood to lymphatic differentiation only occurs in latently infected cells as determined by co-immunofluorescence with LANA and LEC-specific markers in KSHV infected TIME cells (Morris et al., 2008) . Additionally, another study showed similar results with immunofluorescence to Prox1 (Yoo et al., 2010) . Therefore, it is likely that there is a factor expressed only in latently infected cells that is critical for KSHV induced BEC to LEC differentiation. A recent study found that kaposin B, a KSHV gene that is expressed during latency, was able to stabilize Prox-1 mRNA through sequences in its 3'UTR (Yoo et al., 2010) However, kaposin B alone was not sufficient to induce expression of Prox1 in BECs. Therefore, two events must occur: (1) KSHV induces the expression of Prox-1 and (2) once expressed, kaposin B stabilizes and effectively increases expression of Prox-1 to drive differentiation. Therefore, a lytic gene could theoretically induce the expression of Prox-1 to low levels in a paracrine fashion while kaposin B stabilizes and effectively increases the expression of Prox-1 to levels sufficient to fully drive BEC to LEC differentiation in the latently infected cells but not the surrounding uninfected cells. While we demonstrate here that vIL-6 is certainly sufficient to turn on the expression of Prox-1 and could act as this paracrine factor, it is not essential for KSHV induced BEC to LEC differentiation. This indicates that KSHV expresses another gene that is capable of activating STAT3, AKT and lymphatic reprogramming. We found that vIL-6 is unlikely to play the predominant role in activation of gp130 signaling during latent infection as knockdown of vIL-6 did not decrease the activation of gp130 signaling in KSHV infected cells or from KSHV conditioned media but was able to significantly decrease paracrine signaling from vIL-6 expressing cells. This suggests that another viral gene(s) is expressed during latency that is responsible for gp130 receptor signaling, or there is another untested lytic gene capable of activating gp130 in a paracrine fashion. It is also possible that the 17 or more KSHV miRNAs play a significant role in the regulation of this pathway. Further work is underway to determine if expression of the KSHV miRNAs alter endothelial cell differentiation. Nonetheless, our findings imply that there are redundant methods used by KSHV to activate the gp130 receptor and lymphatic reprogramming, which would predict an important role for this signaling pathway in KSHV pathogenesis.
Materials and methods
Reagents and antibodies
Phospho-AKT (Ser473), pan AKT, phospho-STAT3 (Y705) and pan STAT3 antibodies (Cell Signaling Technologies) were used as specified by the manufacturer. Antibodies to b-actin (Sigma), ORF59 (Advanced Biotechnologies, Inc.), LANA (Advanced Biotechnologies, Inc. and kind gift of D. Ganem), gp130, VEGFR-3 (Santa Cruz Biotechnologies), and podoplanin (Abcam) were used in immunoblot or immunofluorescence analysis as outlined below. Kinase inhibitors AG490 and LY294002 (Calbiochem) were reconstituted in DMSO and used at the concentrations specified.
Cells TIME cells and primary dermal blood microvascular endothelial cells (Lonza) were maintained as monolayer cultures in EGM-2 media [Lonza (Lagunoff et al., 2002; Venetsanakos et al., 2002) ]. BCBL-1 cells (Renne et al., 1996) were maintained in RPMI 1640 media (Cellgro, Mediatech, Inc.) supplemented with 10% fetal bovine serum, penicillin, streptomycin, L-glutamine and b-mercaptoethanol. HEK293T cells and Phoenix-ampho packaging cell lines were obtained from American Type Culture Collection (ATCC) and were maintained in DMEM (Cellgro, Mediatech, Inc.) supplemented with 10% fetal bovine serum, penicillin, streptomycin, and L-glutamine.
KSHV viruses and infections
KSHV inoculum, from BCBL-1 cells, was used to infect TIME cells as previously described (Lagunoff et al., 2002; Punjabi et al., 2007) . Briefly, KSHV infections of TIME cells were performed in serum free EBM-2 media for 3 h, after which the media was replaced with complete EGM-2 containing serum and supplements. Infection rates were assessed by immunofluorescence using antibodies against the latent protein LANA and the lytic protein ORF59 and only experiments with greater than 90% LANA positive cells and less than 1% ORF 59 positive cells were used.
Plasmids
The KSHV latent genes vCyclin and kaposin A were cloned by PCR into the 3XFLAG-CMV-10 expression vector (Sigma) using KpnI and XbaI restriction sites, and kaposin B and C were subcloned from pCR3.1 into the HindIII and EcoRI restriction sites (pCR3.1-kaposin B and pCR3.1-kaposin C plasmids obtained from Craig McCormick, Dalhousie University). FLAG-vFLIP with codons optimized for expression was a kind gift from Don Ganem (University of California San Francisco, P. Bellare and D. Ganem, unpublished data). A retroviral plasmid encoding LANA, pBABE-LANA, was a kind gift from Adam Grundhoff (Heinrich-Pette-Institute for Experimental Fig. 6 . Knockdown of vIL-6 inhibits conditioned media from vIL-6 expression cells from inducing STAT3 but not from KSHV infected cells. (A) TIME cells were infected with KSHV, 24 hpi cells were transduced with lentiviruses encoding nonspecific shRNA (NS) or a vIL-6-specific shRNA. Cell lysates were harvest 48 h after transduction and subjected to immunoblot analysis with the indicated antibodies. Knockdown of vIL-6 had little or no effect on expression of lymphatic genes or STAT3 activation in infected cells. The numbers below the lanes indicated the relative abundance of phospho-STAT3 normalized to total STAT3 expression in each lane compared to expression in the NS control cells. (B) TIME cells were infected and transduced with vIL-6 specific or nonspecific shRNAs as in A. At 40 h post lentiviral transduction, the media was changed, conditioned media was harvested 8 h later and used to treat serum-starved TIME cells for 30 mins. As a control for vIL-6 knockdown, vIL-6 expressing TIME cells were concurrently infected with the shRNA lentiviruses and either pCGSW or vIL-6 expressing lentivirus. The vIL-6 shRNA decreased the phosphorylation of STAT3 by conditioned media harvested from control vIL-6 expressing cells (lanes 7 and 8), but not from KSHV-infected cell conditioned media (lanes 3 and 4) . The numbers below the lanes indicated the relative abundance of phospho-STAT3 normalized to total STAT3 expression in each lane compared to expression in the NS control cells.
Virology and Immunology, University of Hamburg). The following retroviral expression vectors were used: pLNCX2 (Clontech); hemaglutinin-tagged K3, pLNCX-HA-K3; FLAG-tagged K5, pBMN-FLAG-K5; pLNCX-K14 [kind gifts from Laurant Coscoy, University of California Berkley (Coscoy and Ganem, 2000) ]; pBMN-ZIN; and pBMN-vIL-6 (vIL-6 cloned by PCR into the BamH1 and EcoR1 sites of pBMN-ZIN). Lentiviral packaging plasmids psPAX2 and pMD2.G were obtained from Addgene (supplied by Dr. Didier Trono). Lentiviral expression plasmids pSIN-MCS containing KSHV genes (Vart et al., 2007) or pCGSW (Godfrey et al., 2005) encoding GFP were described elsewhere. Lentiviral shRNA vectors to vIL-6 and nonspecific, nonsilencing (NS) control are described elsewhere [gifts from John Nicholas, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine (Chen et al., 2009) ].
Transient transfection of plasmids by Amaxa nucleofection TIME cells (1 Â 10 6 cells) were transfected with 4 mg of the plasmids encoding the latent genes using the Amaxa Nucleofector (Koeln, Germany) according to the manufacturer's protocol. 72 h post transfection, cells were harvested and analyzed by immunoblot analysis.
Immunoblot analysis
Cells were harvested and resuspended in RIPA lysis buffer (50 mM Tris-HCl, pH 7.6, 150 mM NaCl, 1 mM EDTA, 1% NP-40, 0.5% deoxycholate, 0.1% sodium dodecyl sulfate, 1 mM sodium orthovanadate, 1 mM sodium fluoride, 40 mM b-glycerophosphate, and Complete Mini Protease Inhibitor Tablet [Roche]), cell debris was removed after a 20 min incubation by centrifugation. Protein concentrations were determined by BCA assay (Pierce) and 10 mg protein was fractionated on a sodium dodecyl sulfatepolyacrylamide gel, transferred to polyvinyl difluoride membrane, blotted with the appropriate antibody (dilutions were 1:1000 for anti-pAKT, anti-AKT anti-pSTAT3, anti-STAT3, anti-gp130, anti-VEGFR-3; 1:2500 for anti-podoplanin; and 1:10,000 anti-b-actin), and subsequently probed with horse radish peroxidase-conjugated goat anti-mouse or -rabbit immunoglobulin G (Jackson ImmunoResearch Laboratories). Immunoreactive proteins were visualized by chemiluminescence using Amersham ECL Plus. Differences in band intensity were quantified by densitometric methods (ImageJ program).
RNA isolation and quantitative RT-PCR
Total RNA was isolated from TIME cells using the RNeasy Plus kit (Qiagen). 100 or 500 ng of total RNA was used in SuperScript III, Platinum SYBR green, one-step quantitative reverse transcription PCR (RT-PCR) (Invitrogen) according to manufacturer's protocols with the primers for either GAPDH (glyceraldehydes-3-phosphate dehydrogenase) (forward: 5 0 -GGA CTC ATG ACC ACA GTC CA-3 0 , reverse: 5 0 -CCA GTA GAG GCA GGG ATG AT-3 0 ), Prox1 (forward: 5 0 -AGT GCA ATG CAG GAA GGA TT-3 0 , reverse: 5 0 -CCA CTT GAT GAG CTG AGA GG-3 0 ), gp130 (forward: 5 0 -GAG CCA GAT TCC TCC TGA AG-3 0 , reverse: 5 0 -CCA CTT GCT TCT TCA CTC CA-3 0 ). Relative abundances of the indicated mRNAs were normalized by the delta threshold cycle method to the abundance of GAPDH, with mock-infected TIME cells set to 1. Error bars reflect standard errors of the mean (three experiments).
Retrovirus production and infection of TIME cells
For production of replication-defective amphotropic murine leukemia virions, Phoenix-ampho packaging cells were seeded in a 6-cm dish and transfected with 5 mg of retroviral vector using TransIT 293 protocol (Mirus). 48 h after transfection, the medium containing virions was cleared of cell debris by spinning at 2000 rpm for 10 min, aliquotted directly, and stored at À 80 1C. Retroviral infections were done by incubating 1 mL of virus preparation with 1 Â 10 5 TIME cells and 8 mg/mL polybrene in a 6-well plate, first, by centrifugation at 2000 rpm for 2 h at 37 1C, and then for an additional 3 h in an incubator. 48 h after infection, stable pooled cells were selected with the appropriate antibiotic, 2.5 mg/mL puromycin, 500 mg/mL G418, or 100 mg/mL hygromycin (Cellgro, Mediatech, Inc.).
Lentivirus production and infection of TIME cells
For production of vesicular stomatitis virus-G envelope-pseudotyped lentiviral virions, HEK293T were seeded in a 10-cm dish (5.5 Â 10 6 cells) and were cotransfected the next day with 8 mg psPAX2, 4 mg pMD2.G, and 8 mg of lentiviral (pSIN-MCS or pCGSW) construct using the TransIt 293 protocol (Mirus). 24 h after transfection, the medium was changed, and at 48 and 72 h post transfection, the medium containing the lentiviral virions was harvested, filtered through a 0.45-mM filter, aliquotted directly, and stored at À 80 1C. Lentiviral infections were done by incubating 2 mL of virus preparation with 2 Â 10 5 TIME cells overnight with 8 mg/mL polybrene. Cells were harvested 72 h post infection and GFP expression in the pCGSW-transduced cells was monitored by fluorescent microscopy (Supplemental Fig. 1 ).
RT-PCR to verify expression of KSHV genes from lentiviral constructs
Total RNA was isolated from TIME cells using the RNeasy Plus kit (Qiagen). Approximately 2 mg of total RNA was used to make cDNA with the SuperScript VILO cDNA Synthesis kit (Invitrogen).
Reactions without the addition of reverse transcriptase were used as negative controls. Subsequently, 1 mL of cDNA was used in a PCR reaction with primers to specific KSHV genes or cellular GAPDH (Vart et al., 2007) .
Conditioned medium
Conditioned medium from lentivirus-infected or KSHVinfected TIME cells was harvested 72 h or 24 h post infection respectively. Cell debris was removed by centrifugation in a tabletop centrifuge at 2000 rpm for 10 min, then free virions were removed via centrifugation at 15,000 rpm for 2 h and the clarified medium was stored at À 80 1C. Uninfected TIME cells were serum starved for 2 h before treatment with conditioned medium for 30 min.
